Futuximab

Futuximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	HER1
Clinical data
Other names	992 DS
ATC code	none;
Identifiers
CAS Number	1310460-85-5;
ChemSpider	none;
UNII	B37J680LX0;
Chemical and physical data
Formula	C6468H10002N1724O2055S46
Molar mass	146269.94 g·mol−1

Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It acts as an immunomodulator and also binds to HER1.[2][3]

This drug was developed by Symphogen.

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.
World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD (July 2018). "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. doi:10.1007/s11060-018-2832-6. PMC 5999169. PMID 29564747.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association.

[2] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[3] Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD (July 2018). "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models". J. Neurooncol. 138 (3): 489–498. doi:10.1007/s11060-018-2832-6. PMC 5999169. PMID 29564747.